NewAmsterdam Pharma Price To Book vs. Short Ratio
| NAMS Stock | 26.19 7.67 41.41% |
For NewAmsterdam Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NewAmsterdam Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NewAmsterdam Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NewAmsterdam Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NewAmsterdam Pharma over time as well as its relative position and ranking within its peers.
NewAmsterdam |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewAmsterdam Pharma. If investors know NewAmsterdam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewAmsterdam Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.21) | Revenue Per Share 0.373 | Quarterly Revenue Growth 8.898 | Return On Assets (0.29) | Return On Equity (0.47) |
The market value of NewAmsterdam Pharma is measured differently than its book value, which is the value of NewAmsterdam that is recorded on the company's balance sheet. Investors also form their own opinion of NewAmsterdam Pharma's value that differs from its market value or its book value, called intrinsic value, which is NewAmsterdam Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewAmsterdam Pharma's market value can be influenced by many factors that don't directly affect NewAmsterdam Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewAmsterdam Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewAmsterdam Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewAmsterdam Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NewAmsterdam Pharma Short Ratio vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NewAmsterdam Pharma's current stock value. Our valuation model uses many indicators to compare NewAmsterdam Pharma value to that of its competitors to determine the firm's financial worth. NewAmsterdam Pharma is regarded fourth in price to book category among its peers. It is rated below average in short ratio category among its peers fabricating about 0.65 of Short Ratio per Price To Book. The ratio of Price To Book to Short Ratio for NewAmsterdam Pharma is roughly 1.53 . Comparative valuation analysis is a catch-all technique that is used if you cannot value NewAmsterdam Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NewAmsterdam Short Ratio vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
NewAmsterdam Pharma |
| = | 4.47 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
NewAmsterdam Pharma |
| = | 2.92 X |
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
NewAmsterdam Short Ratio Comparison
NewAmsterdam Pharma is currently under evaluation in short ratio category among its peers.
NewAmsterdam Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NewAmsterdam Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NewAmsterdam Pharma will eventually generate negative long term returns. The profitability progress is the general direction of NewAmsterdam Pharma's change in net profit over the period of time. It can combine multiple indicators of NewAmsterdam Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 4.4 M | 3.6 M | |
| Net Interest Income | 3.4 M | 3.6 M | |
| Interest Income | 11.3 M | 11.8 M | |
| Operating Income | -165.7 M | -157.4 M | |
| Net Loss | -176.9 M | -168.1 M | |
| Income Before Tax | -160.2 M | -152.2 M | |
| Total Other Income Expense Net | 5.5 M | 5.8 M | |
| Net Loss | -25.7 M | -27 M | |
| Net Loss | -176.9 M | -168.1 M | |
| Income Tax Expense | 27 K | 25.6 K | |
| Change To Netincome | -360.9 K | -342.9 K | |
| Net Loss | (2.15) | (2.26) | |
| Income Quality | 0.80 | 0.72 | |
| Net Income Per E B T | 0.99 | 0.88 |
NewAmsterdam Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NewAmsterdam Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NewAmsterdam Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NewAmsterdam Pharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in NewAmsterdam Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run AI Portfolio Architect Now
AI Portfolio ArchitectUse AI to generate optimal portfolios and find profitable investment opportunities |
| All Next | Launch Module |
Use Investing Themes to Complement your NewAmsterdam Pharma position
In addition to having NewAmsterdam Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cancer Fighters Thematic Idea Now
Cancer Fighters
Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. The Cancer Fighters theme has 60 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cancer Fighters Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.